Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) posted its earnings results on Thursday. Fulcrum Therapeutics Stock Up 2.8%FULC traded up $0.10 during trading on Thursday, reaching $3.72. Get Fulcrum Therapeutics alerts:Wall Street Analyst Weigh InFULC has been the topic of a number of recent analyst reports. Fulcrum Therapeutics Company Profile(Get Free Report)Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Read MoreReceive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.